Paul William Ladenson, MD

Professional Titles

• John Eager Howard Professor of Endocrinology & Metabolism

Primary Academic Title

Professor of Medicine

Background

Centers and Institutes

• Heart and Vascular Institute
• Sidney Kimmel Comprehensive Cancer Center
• Welch Center for Prevention, Epidemiology, and Clinical Research

Additional Academic Titles

Professor of Pathology, Professor of Oncology, Professor of Radiology and Radiological Science

Research Interests

Cardiac actions of thyroid hormone, Thyroid cancer, Thyroid hormone analogs

Lab Website

Paul Ladenson Lab

• The Paul Ladenson Lab studies the application of thyroid hormone analogues for treating cardiovascular disease; novel approaches to thyroid cancer diagnosis and management; and the health economic analyses related to thyroid patient care.

Research Summary

Dr. Ladensons research relates to clinical application of novel diagnostic and prognostic markers that could improve recognition and management of thyroid cancer, and new chemotherapeutic approaches to metastatic thyroid cancer.

PubMed

http://www.ncbi.nlm.nih.gov/pubmed?term=Ladenson%20p%5BAuthor%5D&cmd=DetailsSearch

Selected Publications

• Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. “Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012.” J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul.

• Diaz, L.A., Jr.; Foss, C.A.; Thornton, K.; Nimmagadda, S.; Endres, C.J.; Uzuner, O.; Seyler, T.M.; Ulrich, S.D.; Conway, J.; Bettegowda, C.; Agrawal, N.; Cheong, I.; Zhang, X.; Ladenson, P.W.; Vogelstein, B.N.; Mont, M.A.; Zhou, S.; Kinzler, K.W.; Vogelstein, B.; Pomper, M.G. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One. 2007;2(10):e1007.

• Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Samuels M, Graham K, Braverman LE, Skarulis M, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885.

• Hobbs, R.F.; Wahl, R.L.; Lodge, M.A.; Javadi, M.S.; Cho, S.Y.; Chien, D.T.; Ewertz, M.E.; Esaias, C.E.; Ladenson, P.W.; Sgouros, G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009 Nov;50(11):1844-1847.

• Hu, S.; Ewertz, M.; Tufano, R.P.; Brait, M.; Carvalho, A.L.; Liu, D.; Tufaro, A.P.; Basaria, S.; Cooper, D.S.; Sidransky, D.; Ladenson, P.W.; Xing, M. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab. 2006 Jan;91(1):98-104.

• Jonklaas, J.; Cooper, D.S.; Ain, K.B.; Bigos, T.; Brierley, J.D.; Haugen, B.R.; Ladenson, P.W.; Magner, J.; Ross, D.S.; Skarulis, M.C.; Steward, D.L.; Maxon, H.R.; Sherman, S.I. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec;20(12):1423-1424.

• Ladenson PW, Braverman LE, Mazzaferri EL, Robbins J, Cooper DS, Garber JS, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Levis S, Hay ID, McEllin K, Moscicki R, Weintraub BD. Comparison of recombinant human thyrotropin administration to thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. New Engl J Med 1997;337:888-96.

• Ladenson, P.W. Thyroid Hormone Analogues: Ready for Prime Time. Thyroid. 2010 Dec 27;21(2):101-102.

• Ladenson, P.W.; Kristensen, J.D.; Ridgway, E.C.; Olsson, A.G.; Carlsson, B.; Klein, I.; Baxter, J.D.; Angelin, B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010 Mar 11;362(10):906-916.

• Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the Incremental Value of Recombinant TSH Stimulation before FDG PET/CT Imaging to Localize Residual Differentiated Thyroid Cancer J Clin Endocrinol Metab 2009;94:1310-1316.

• Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. “Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the Baltimore longitudinal study of aging.” Thyroid. 2015 Sep;25(9):979-86. doi: 10.1089/thy.2015.0180. Epub 2015 Aug 13.

• McLeod DS, Cooper DS, Ladenson PW, Whiteman DC, Jordan SJ. “Race/ethnicity and the prevalence of thyrotoxicosis in young Americans.” Thyroid. 2015 Jun;25(6):621-8. doi: 10.1089/thy.2014.0504. Epub 2015 May 8.

• McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. “Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis.” Thyroid. 2015 Oct;25(10):1097-105. doi: 10.1089/thy.2015.0148. Epub 2015 Aug 24.

• Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos R, Sherman S, Haugen B, Corone C, Molinaro E, Elisei, Ceccarelli C, Pinchera A, Wahl R, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32.

• Prideaux, A.R.; Song, H.; Hobbs, R.F.; He, B.; Frey, E.C.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun;48(6):1008-1016.

• Roopnarinesingh N, Brennan N, Khan C, Ladenson PW, Hill-Briggs F, Kalyani RR. “Barriers to optimal diabetes care in Trinidad and Tobago: a health care Professionals' perspective.” BMC Health Serv Res. 2015 Sep 19;15(1):396. doi: 10.1186/s12913-015-1066-y.

• Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A Comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84. 

• Sgouros, G.; Song, H.; Ladenson, P.W.; Wahl, R.L. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec;47(12):1977-1984.

• Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New Engl J Med 2005;352:2406-2412.

• Song, H.; He, B.; Prideaux, A.; Du, Y.; Frey, E.; Kasecamp, W.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006 Dec;47(12):1985-1994.

• Xing M, Tufano RP, Tufaro AP, Basaria S, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004;89:2867-72.

• Xing M, Westra WH, M.D., Tufano RP, Rosenbaum E, Cohen Y, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz ME, Tufaro AP, Califano JA, Ringel MD., Zeiger MA., Sidransky D, and Ladenson PW. BRAF mutation predicts a poorer prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.

Honors

Lewis E. Braverman Lectureship Award, American Thyroid Association, 1/1/12